CCL20, a direct-acting pro-angiogenic chemokine induced by hepatitis C virus (HCV): Potential role in HCV-related liver cancer

被引:51
作者
Benkheil, Mohammed [1 ]
Van Haele, Matthias [2 ]
Roskams, Tania [2 ]
Laporte, Manon [1 ]
Noppen, Sam [1 ]
Abbasi, Kayvan [1 ]
Delang, Leen [1 ]
Neyts, Johan [1 ]
Liekens, Sandra [1 ]
机构
[1] Univ Leuven KU Leuven, Rega Inst Med Res, Lab Virol & Chemotherapy, Leuven, Belgium
[2] Univ Leuven KU Leuven, Dept Imaging & Pathol, Translat Cell & Tissue Res, Leuven, Belgium
关键词
Chemokine; Angiogenesis; Hepatocellular carcinoma; Hepatitis C virus; LIGAND; 20; EXPRESSION; INFECTION; RECEPTOR; CELLS; ACTIVATION; PATHWAYS;
D O I
10.1016/j.yexcr.2018.09.023
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The CCL20/CCR6 chemokine/receptor axis has previously been shown to contribute to the initiation and progression of hepatocellular carcinoma (HCC) through the recruitment of CCR6-positive leukocytes to the tumor microenvironment. In particular, high serum levels of CCL20 are reported in patients with HCC induced by the hepatitis C virus (HCV). A potential non-immune role for the CCL20/CCR6 axis in HCC development has not yet been investigated. Microarray analysis (Benkheil et al., paper submitted for publication), revealed that CCL20 is highly upregulated in hepatoma cells infected with HCV compared with non-infected hepatoma cells. To determine the role of the CCL20/CCR6 axis in HCV-related HCC, we first explored which cell populations express CCR6 in human liver tissue with chronic disease or HCC. Immunohistochemical (IHC) analysis revealed that CCR6 is present on endothelial cells (ECs) of portal blood vessels in livers with chronic HCV infection and in HCV- and alcoholic-HCC tissue. In addition, we found CCR6 to be expressed on primary macrovascular (HUVECs) and microvascular ECs (HMVEC-ds) where it co-expressed with the endothelial marker CD31. In vitro angiogenesis experiments revealed that CCL20 is a direct pro-angiogenic molecule that induces EC invasion, sprouting and migration through CCR6. Moreover, using the angiogenesis matrigel plug assay in immunodeficient NMRI-nu mice, we clearly showed that CCL20 induces blood vessel formation, by attracting CCR6-positive ECs. Finally, we demonstrated that HCV-induced CCL20 protein expression and secretion in hepatoma cells could be abolished by antiviral treatment, indicating that CCL20 expression is dependent on HCV replication. In contrast to HCV, HBV-infection resulted in a decreased expression of CCL20, implying a virus-specific effect. Taken together, we identified HCV-induced CCL20 as a direct pro-angiogenic factor that acts on endothelial CCR6. These results suggest that the CCL20/CCR6 axis contributes to hepatic angiogenesis, promoting the hypervascular state of HCV-HCC.
引用
收藏
页码:168 / 177
页数:10
相关论文
共 48 条
  • [21] Can Hepatitis C Virus (HCV) Direct-Acting Antiviral Treatment as Prevention Reverse the HCV Epidemic Among Men Who Have Sex With Men in the United Kingdom? Epidemiological and Modeling Insights
    Martin, Natasha K.
    Thornton, Alicia
    Hickman, Matthew
    Sabin, Caroline
    Nelson, Mark
    Cooke, Graham S.
    Martin, Thomas C. S.
    Delpech, Valerie
    Ruf, Murad
    Price, Huw
    Azad, Yusef
    Thomson, Emma C.
    Vickerman, Peter
    CLINICAL INFECTIOUS DISEASES, 2016, 62 (09) : 1072 - 1080
  • [22] Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia
    Alavi, Maryam
    Law, Matthew G.
    Valerio, Heather
    Grebely, Jason
    Amin, Janaki
    Hajarizadeh, Behzad
    Selvey, Christine
    George, Jacob
    Dore, Gregory J.
    JOURNAL OF HEPATOLOGY, 2019, 71 (02) : 281 - 288
  • [23] All-oral direct-acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV-coinfected subjects in real-world practice: Madrid coinfection registry findings
    Berenguer, Juan
    Gil-Martin, Angela
    Jarrin, Inmaculada
    Moreno, Ana
    Dominguez, Lourdes
    Montes, Marisa
    Aldamiz-Echevarria, Teresa
    Tellez, Maria J.
    Santos, Ignacio
    Benitez, Laura
    Sanz, Jose
    Ryan, Pablo
    Gaspar, Gabriel
    Alvarez, Beatriz
    Losa, Juan E.
    Torres-Perea, Rafael
    Barros, Carlos
    San Martin, Juan V.
    Arponen, Sari
    de Guzman, Maria T.
    Monsalvo, Raquel
    Vegas, Ana
    Garcia-Benayas, Maria T.
    Serrano, Regino
    Gotuzzo, Luis
    Antonia Menendez, Maria
    Belda, Luis M.
    Malmierca, Eduardo
    Calvo, Maria J.
    Cruz-Martos, Encarnacion
    Gonzalez-Garcia, Juan J.
    HEPATOLOGY, 2018, 68 (01) : 32 - 47
  • [24] Effect of direct-acting antivirals on platelet-associated immunoglobulin G and thrombocytopenia in hepatitis C virus-related chronic liver disease
    Honma, Yuichi
    Shibata, Michihiko
    Hayashi, Tsuguru
    Kusanaga, Masashi
    Ogino, Noriyoshi
    Minami, Sota
    Kumei, Shinsuke
    Oe, Shinji
    Miyagawa, Koichiro
    Senju, Michio
    Matsuoka, Hidehiko
    Watanabe, Tatsuyuki
    Hiura, Masaaki
    Abe, Shintaro
    Harada, Masaru
    LIVER INTERNATIONAL, 2019, 39 (09) : 1641 - 1651
  • [25] Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis
    Yuki Tahata
    Hayato Hikita
    Satoshi Mochida
    Nobuyuki Enomoto
    Norifumi Kawada
    Masayuki Kurosaki
    Akio Ido
    Daiki Miki
    Hitoshi Yoshiji
    Yasuhiro Takikawa
    Ryotaro Sakamori
    Yoichi Hiasa
    Kazuhiko Nakao
    Naoya Kato
    Yoshiyuki Ueno
    Hiroshi Yatsuhashi
    Yoshito Itoh
    Ryosuke Tateishi
    Goki Suda
    Taro Takami
    Yasunari Nakamoto
    Yasuhiro Asahina
    Kentaro Matsuura
    Taro Yamashita
    Tatsuya Kanto
    Norio Akuta
    Shuji Terai
    Masahito Shimizu
    Satoshi Sobue
    Tomokatsu Miyaki
    Akihiro Moriuchi
    Ryoko Yamada
    Takahiro Kodama
    Tomohide Tatsumi
    Tomomi Yamada
    Tetsuo Takehara
    Journal of Gastroenterology, 2022, 57 : 120 - 132
  • [26] Postoperative direct-acting antiviral treatment after liver resection in patients with hepatitis C virus-related hepatocellular carcinoma
    Tanaka, Shogo
    Shinkawa, Hiroji
    Tamori, Akihiro
    Takemura, Shigekazu
    Uchida-Kobayashi, Sawako
    Amano, Ryosuke
    Kimura, Kenjiro
    Ohira, Go
    Nishio, Kohei
    Tauchi, Jun
    Kinoshita, Masahiko
    Kawada, Norifumi
    Kubo, Shoji
    HEPATOLOGY RESEARCH, 2021, 51 (11) : 1102 - 1114
  • [27] Assessment of hepatic fibrosis, portal hemodynamic changes, and disease severity in patients with HCV-related liver cirrhosis after sustained virologic response to direct-acting antiviral drugs (DAAs)
    Hassan, Waleed Attia
    Kamel, Sherif I.
    Mahmoud, Ibrahim Abdel Naby
    Makhlouf, Nahed
    Moubark, Mahmoud
    Hassany, Sahar M.
    EGYPTIAN LIVER JOURNAL, 2023, 13 (01)
  • [28] Single-Center Experience in Pre-transplant Hepatitis C Virus (HCV) Treatment Among Living Donor Liver Transplant Candidates: Bridging the Direct-Acting Antivirals (DAA)
    Niranjan-Azadi, Ashwini M.
    Kabacam, Gokhan
    Durand, Christine M.
    Anjum, Saad
    Saberi, Behnam
    Dagher, Nabil N.
    Philosophe, Benjamin
    Gurakar, Ahmet
    ANNALS OF TRANSPLANTATION, 2017, 22 : 570 - 574
  • [29] Oral Direct-Acting Antiviral Therapy to Prevent Reinfection of the Liver Graft After Liver Transplantation for Hepatitis C Virus-Related Cirrhosis
    Kwo, Paul Y.
    Tector, A. Joseph
    LIVER TRANSPLANTATION, 2013, 19 (07) : 780 - 781
  • [30] Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network ActivityLINA cohort)
    Gentile, Ivan
    Scotto, Riccardo
    Coppola, Carmine
    Staiano, Laura
    Amoruso, Daniela Caterina
    De Simone, Teresa
    Portunato, Federica
    De Pascalis, Stefania
    Martini, Salvatore
    Macera, Margherita
    Viceconte, Giulio
    Tosone, Grazia
    Buonomo, Antonio Riccardo
    Borgia, Guglielmo
    Coppola, Nicola
    HEPATOLOGY INTERNATIONAL, 2019, 13 (01) : 66 - 74